Celgene Adds New Fusion Protein to Portfolio with Delinia Acquisition

January 26, 2017
Randi Hernandez

Randi Hernandez was science editor at BioPharm International from September 2014 to May 2017.

The company will gain the rights to a mutein that is believed to help maintain immune system homeostasis.

Celgene will further bolster its capabilities in immunology and autoimmune disorders with the acquisition of the biotechnology company Delinia, a move Celgene announced on Jan. 26, 2017. With the company comes the ownership of DEL106, a novel IL-2 mutein Fc fusion protein that is designed to upregulate regulatory T cells (Tregs).

Tregs maintain tolerance to self-antigens and are instrumental in the prevention of autoimmune diseases. Thus, Tregs are immunosuppressive and work to downregulate induction and proliferation of effector T cells. The cytokine IL-2 normally activates effector cells, but also drives expansion of Tregs to regulate the effector cells.

Celgene will pay Delinia an initial payment of $300 million, with additional payments of up to $475 million upon the development, regulatory, and commercial advances related to DEL106. DEL-106 is expected to start clinical trials in 2018.

Source: Celgene

Related Content:

News | Biopharma News